SCHEMBL22101592

SCHEMBL22101592

O=C(O)C1CCC1c1cncnc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.39
HDAC4 P56524 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
TBXA2R P21731 1/20 0.35
AKR1C3 P42330 1/20 0.34
AKR1C1 Q04828 1/20 0.34
FFAR1 O14842 3/20 0.34
GPR88 Q9GZN0 1/20 0.34
ADORA1 P30542 1/20 0.33
GABRR1 P24046 1/20 0.32
IDO1 P14902 1/20 0.31
POLB P06746 1/20 0.31
TSHR P16473 1/20 0.31
NAMPT P43490 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31076243 0.86 FFAR1 (0.46) HCAR2HDAC4HRH3FFAR1GPR88
SCHEMBL32677636 0.86 FFAR1 (0.46) HCAR2HDAC4HRH3FFAR1GPR88
SCHEMBL15590483 0.74 AKR1C3 (0.55) HDAC4HRH3AKR1C3AKR1C1FFAR1
SCHEMBL1073458 0.74 AKR1C3 (0.55) HDAC4HRH3AKR1C3AKR1C1FFAR1
SCHEMBL31076190 0.73 GPR88 (0.39) HCAR2HDAC4HRH3GPR88NAMPT
SCHEMBL22101598 0.72 HRH3 (0.51) HCAR2HDAC4HRH3ADORA1
SCHEMBL29496340 0.70 SLC6A12 (0.39) HCAR2HDAC4GPR88
SCHEMBL20581460 0.70 FFAR1 (0.37) TBXA2RFFAR1ADORA1POLBTSHR
SCHEMBL20581463 0.67 TBXA2R (0.36) HRH3TBXA2RFFAR1GABRR1TSHR
SCHEMBL20581156 0.67 ALDH1A1 (0.35) HDAC4GABRR1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017525-A1 CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-01-20 US disclosed
WO-2020123271-A1 CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017525-A1 CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS PDE9A, PDE5A, PDE3B HCAR2 1424/4885HDAC4 617/4885HRH3 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.